Zytorvi 240 mg contains Toripalimab, a humanized monoclonal antibody that targets the programmed death-1 (PD-1) receptor on T-cells. It is administered via intravenous infusion under oncology supervision and is part of modern immunotherapy treatments.

🔬 Mechanism of Action

Toripalimab binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2 ligands. As a result, it:

• Restores T-cell immune response
• Enhances immune-mediated tumor cell destruction
• Helps control tumor growth and progression

This immune checkpoint inhibition allows the body’s immune system to more effectively fight cancer.

💊 Indications

Zytorvi 240 mg is indicated for:

• Nasopharyngeal Carcinoma (NPC)
• Melanoma
• Other advanced or metastatic solid tumors as per approved clinical use and guidelines

It is often used alone or in combination with chemotherapy depending on the indication.

📌 Key Features

• Strength: 240 mg
• Dosage Form: Intravenous infusion
• Therapeutic Class: PD-1 Immune Checkpoint Inhibitor
• Administration: Given as IV infusion in hospital or oncology setting
• Monitoring: Liver, kidney, thyroid function, and immune-related adverse events monitoring required

⚕️ Benefits

• Advanced immunotherapy for multiple cancers
• Enhances natural immune response
• Provides durable treatment responses
• Can be used in combination therapy

⚠️ Precautions

• Risk of immune-related adverse reactions (pneumonitis, colitis, hepatitis, endocrinopathies)
• Infusion-related reactions may occur
• Requires close monitoring during treatment
• Use strictly under oncologist supervision

Zytorvi 240 mg (Toripalimab Injection) is a cutting-edge immunotherapy that helps activate the body’s immune system to fight cancer, offering improved outcomes in selected advanced malignancies when administered under expert medical care.